Background and Purpose-Lipoprotein(a) [Lp(a)] level is an established risk factor for coronary artery disease and has been implicated in carotid artery disease (CAAD). The relationship between genetic variation in the LPA gene region and CAAD risk remains unknown. Methods-We genotyped single nucleotide polymorphisms (SNPs) in the LPAL2, LPA, and PLG regions in 530 individuals with severe CAAD and 770 controls and kringle IV type 2 (KIV2) repeat length in a subset of 90 individuals. Results-Nine SNPs collectively accounted for 30% of the variance in Lp(a) level. Six SNPs were associated with Lp(a) level after accounting for KIV2 copy number, and the dominant KIV2 allele combined with these markers explained 60% of the variance in Lp(a) level. Five SNPs, including rs10455872, which had an odds ratio of 2.1 per minor allele and haplotypes formed by rs10455872, rs6919346, and rs3123629, were significant predictors of CAAD. After accounting for Lp(a) level, all evidence of CAAD-genotype association in the LPA region was eliminated. Conclusions-LPA region SNPs capture some but not all of the effect of KIV2 repeat length on Lp(a) level. There are associations between LPA region SNPs and CAAD that appear to be attributable to effects on Lp(a) level. (Stroke. 2011;42:2-9.)
C arotid artery disease (CAAD) is an important preventable risk factor for stroke, which is a leading cause of mortality and long-term disability in the United States. 1 Effective medical and surgical therapies for primary and secondary prevention of stroke are available, but many of these interventions are expensive when viewed in terms of the number of patients needed to treat and the cost to prevent one stroke. 2 Therefore, it remains important to distinguish individuals at low risk for cerebrovascular disease from those at high risk. The heritability of CAAD [3] [4] [5] [6] [7] [8] suggests that genetic data may help to refine risk estimates and thus better target preventative therapies.
Elevated levels of lipoprotein(a) [Lp(a)], a small lowdensity lipoprotein-like particle formed by apolipoprotein B covalently bound to apolipoprotein(a), confer increased risk for CAAD and ischemic stroke. 9, 10 The apolipoprotein(a) protein varies in size because of a copy number polymorphism of the kringle IV type 2 domain (KIV2) encoded by exons 4 through 5ϩ2(nϪ1) of LPA on chromosome 6q26, where n, ranging from 5 to Ͼ50, 11 is the number of KIV2 copies. The KIV2 polymorphism has been reported to account for 69% of the variability in Lp(a) level, 12 with increased repeat number leading to impaired liver secretion, 13 lower plasma Lp(a) level, 11, 12, 14, 15 and decreased risk of myocardial infarction. 16, 17 Although many risk factors overlap between CAAD and coronary artery disease, the relative importance of nongenetic risk factors varies between these two disease processes, 18 suggesting the possibility of differential underlying genetic diatheses. In addition, although many well-established genetic risk factors for coronary artery disease also increase risk for CAAD, 19, 20 some loci, such as that on chromosome 10q11.21, appear to increase risk for coronary artery disease but not stroke; 20 however, other genetic factors, such as dyslipidemia genetic risk scores, display much weaker effects on CAAD. 21 Therefore, given the known association between Lp(a) levels and CAAD, and the reported association between LPA polymorphisms and coronary artery disease, 22 we evaluated the role of LPA region polymorphisms in predicting Lp(a) level and CAAD risk. For polymorphisms associated with Lp(a), we determined whether these effects were attributable to linkage disequilibrium (LD) with the KIV2 repeat. Because of the labor-intensive, low-throughput assays required for accurate KIV2 genotyping, 23 we also sought to determine whether LPA polymorphisms in LD with the KIV2 copy number polymorphism could act as an adequate surrogate for KIV2 genotype in predicting Lp(a) level. Finally, we sought to determine whether LPA polymorphisms contribute to CAAD risk because of, or in addition to, their effects on Lp(a) level.
Materials and Methods

Study Population
All study participants were ascertained at four Seattle medical centers and gave written informed consent. The University of Washington, Virginia Mason Medical Center, and the Puget Sound Veterans Affairs Health Care System human subject review boards approved this study. Characteristics of study participants, clinical covariates, and phenotyping are shown in Table 1 and are described in greater detail elsewhere. 21, 24, 25 Three-hundred six CAAD cases and 534 controls overlap with the cohort described by Ober et al, 26 which analyzed the effects of rs6919346 and rs14224 on Lp(a) level. Briefly, CAAD cases have Ͼ80% internal carotid artery stenosis, in one or both arteries, detected by duplex ultrasound or on previous endarterectomy. Controls have Ͻ15% internal carotid artery stenosis bilaterally and no other known vascular disease. Individuals with carotid stenosis between 50% and 80% were included in analyses testing for association between single nucleotide polymorphisms (SNPs) and Lp(a) but not case vs control analyses. The distributions of censored ages were approximately matched between cases and controls based on the age of diagnosis for CAAD cases and the age at the last blood draw for controls. Because of the limited numbers of other ethnic groups, analyses are limited to individuals of white ancestry, which was confirmed using STRUCTURE 27 considering a panel of ancestry informative markers on the Illumina HumanCVD BeadChip. 28 We excluded any individual who showed Ͼ10% nonwhite ancestry.
Lp(a) Measurement and KIV2 Copy Number
Lp(a) concentrations in nmol/L were measured on fasting plasma samples by a double monoclonal antibody-based enzyme-linked immunoassay as described. 29 The apo(a) size isoforms, defined by the relative number of KIV2 repeats, were determined in a subset of 90 subjects by high-resolution sodium dodecyl sulfate-agarose gel electrophoresis followed by immunoblotting, as previously described. 30, 31 Subjects were overselected for infrequent SNP genotypes to increase genetic diversity in the subsample. The repeat number of the predominantly expressed isoform was used as the analysis trait; 26 in 8 individuals with equally expressed isoforms the two repeat numbers were averaged.
Genotyping and SNP Selection
Genotyping was performed using the Illumina HumanCVD BeadChip platform. 32 The available region on chromosome 6q26-27 included Ϸ318 kb and encompassed the genes LPAL2, LPA, and PLG. A total of 53 SNPs were present within this region and met quality-control criteria for missing genotype rate (Ͻ10%) and minor allele frequency (Ͼ1%). Two SNPs (rs3127569 and rs783144) were excluded because of departure from Hardy-Weinberg equilibrium. Missing genotypes were imputed by BIMBAM 33 based on unphased genotypes for CEU (CEPH European) individuals from HapMap release 27. 34 To reduce the dependence among SNP attributable to LD, we used ldSelect 35 to identify 28 tagSNPs using the default correlation threshold of 0.64. Haplotypes were estimated using PLINK. 36 
Statistical Analyses
All analyses were performed in R 37 and PLINK. Lp(a) level was natural log-transformed because of right skew; in all analyses, Lp(a) level refers to the log-transformed values. Unless otherwise specified, Lp(a) levels were adjusted for gender and age at the time of blood draw. CAAD was adjusted for gender, censored age, body mass index, type 2 diabetes, current smoking status, and total pack-years smoked. Cholesterol levels, use of lipid-lowering medications, and use of antihypertensive medications were not included as covariates for CAAD regression models because, consistent with guidelines, individuals with CAAD in our study are generally treated to lower cholesterol 38 and blood pressure 39 targets than individuals without disease. Thus, including lipid and blood pressure measurements or treatment status would lead to a problematic model in which the dependent variable, case versus control status, is causal for these independent variables. Linear and logistic regressions were used to test for associations between the minor allele dose of each SNP and Lp(a) levels and CAAD status, respectively. Haplotypebased tests of association were performed in PLINK. The proportion of Lp(a) level variance explained was estimated by the difference in adjusted r 2 values between models, which accounts for the number of explanatory terms.
To account for multiple testing, we performed Bonferroni corrections or estimated false discovery rates (FDR) using the Benjamini Hochberg procedure. 40 Bonferroni corrections assume independence of tests and are conservative in the presence of correlated tests, so to estimate a family-wise error rate in the setting of LD between SNP we permuted CAAD status and nongenetic covariates 10 000 times, and for each permutation we determined the most significant association across the 28 tagSNPs. To identify associations between multiple SNPs and Lp(a) while removing SNPs associated with Lp(a) solely attributable to LD with other variants, we used backward stepwise regression.
We assessed the power of our sample size to detect association between SNPs and CAAD case versus control status, conservatively assuming an underlying variant that confers a relative risk of 2.0 for homozygotes and 1.5 in the heterozygotes. 22, 41, 50 As shown in Supplementary Table I (available online at http://stroke.ahajournals.org), our Means or percentages are shown for each trait. P for comparison between cases with at least 80% carotid stenosis vs controls with Ͻ15% stenosis using 2 tests for categorical variables or t tests for continuous variables.
sample size provides robust power to detect association with risk allele frequencies as low as 0.05 when either the causal SNP itself or the surrounding markers in LD are tested.
Results
Prediction of Lp(a) Level by SNPs
As expected, we found that Lp(a) level was elevated in women, older individuals, and individuals with vascular disease. Lp(a) level was significantly higher in CAAD cases than in controls (␤ϭ0.74; Pϭ5.7ϫ10 Ϫ6 ), adjusting for gender, age, body mass index, current smoking and total packyears smoked, diabetes, and use of antihypertensives and lipid-lowering medication. After excluding CAAD status from the regression, only female gender (␤ϭ0.48; Pϭ0.031) and age (␤ϭ0.017; Pϭ0.037) were predictive of elevated Lp(a) level.
Multiple SNPs individually and jointly predict Lp(a) level. We found that 20 out of 28 tagSNPs were associated with Lp(a) level at Pϭ0.05, corresponding to a FDR of 0.067 (Table 2) . Using backward stepwise regression identify a multi-SNP model in which redundant associations attributable to LD were discarded, 9 SNPs were jointly associated with Lp(a) at an inclusion Pϭ0.05, corresponding to a FDR of 0.0064. These 9 SNPs, shown in order of inclusion in Figure 1 , explained 30% of the variance in log e -transformed Lp(a) levels in the complete cohort and 27% in controls.
Haplotypes formed by these 9 SNPs showed significant association with Lp(a) levels but did not improve the percent variance explained compared to the multi-SNP model. The minor alleles of rs10455872 and rs3798820 mark haplotypes carrying short KIV2 alleles and are associated with elevated Lp(a) levels. In a global search of all 2-and 3-SNP haplo- types, the minor allele haplotypes (GA and AG) of these 2 SNP were the strongest predictors of elevated Lp(a) ( Table  3) . To determine whether a haplotype associated with elevated Lp(a) on the major allele backgrounds of rs10455872 and rs3798820 could be identified, we analyzed all possible combinations of 2 and 3 SNP haplotypes formed from the 7 remaining SNPs. One haplotype marked by several SNPs, including GA of rs6919346 and rs2295368 and GCA of rs6919346, rs3798221, and rs2295368, was associated with higher Lp(a) level (Bonferroni-corrected Pϭ4.1ϫ10 Ϫ12 and 8.3ϫ10
Ϫ18 for 21 and 35 2-and 3-SNP haplotypes tested, respectively). However, models explicitly including this haplotype did not account for much more variance in Lp(a) level (25%) than the model that included the underlying SNPs as independent additive covariates (24%).
KIV2 Copy Number Effects
We assayed KIV2 repeat length in a subset of 90 individuals who were approximately representative of 1496 individuals for whom Lp(a) levels were measured. The distribution of Lp(a) level was indistinguishable between these 90 individuals selected for KIV2 typing compared with the complete sample (Kolmogorov-Smirnov Pϭ0.64), as were the frequencies of CAAD cases and controls (Fisher test Pϭ0.66). The Haplotype analyses were performed using covariates as described in Materials and Methods. *Haplotypes among the set tested with the largest ␤ for Lp(a) or OR for CAAD. †P are for the global test of no difference between haplotypes vs any differences and are Bonferroni-corrected for the number of haplotypes tested. ‡Conditional on the major allele (AA) background of rs3798220 and rs10455872.
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distributions of all nongenetic covariates were similar between the subsample and complete sample (data not shown). Although 6 SNPs showed significantly greater minor allele frequencies in the subsample at Pϭ0.05 (Supplementary  Table II available online at http://stroke.ahajournals.org), these SNPs did not tend to be better predictors of Lp(a) level conditional on KIV2 effects (Figure 1) . Although the KIV2 copy number polymorphism alone accounted for a greater percentage of Lp(a) level variation than the 9 SNPs described, SNPs added independent explanatory power not captured by the kringle genotype (upper curve in Figure 1 ). The dominant KIV2 repeat length (see Materials and Methods) showed significant association with Lp(a) level (Pϭ1.1ϫ10 Ϫ4 ) and, conditional on this dominant repeat, there was no further information for Lp(a) prediction provided by either the short (Pϭ0.58) or the long (Pϭ0.89) isoform. The dominant KIV2 repeat length combined with 6 SNPs included in backward stepwise regression at Pϭ0.05 (FDRϭ0.16) accounted for 60% of the variation in log e Lp(a) in the subset of 90 individuals for whom KIV2 genotypes were assayed and for 57% in controls alone. Although the FDR is rather liberal, the 2 weakest predictors, rs3798220 and rs10455872 (Pϭ0.0083 and Pϭ0.034, respectively), have previously been shown to predict Lp(a) level conditional on KIV2 repeat number. 41, 42 
Prediction of CAAD by SNPs
Five SNPs, spanning 3 separate LD blocks, showed significant association with CAAD at Pϭ0.05, corresponding to a FDR of 0.19 ( Figure 2 and Table 2 ). All 5 SNPs showed significant association with Lp(a) level, and for each SNP the same allele associated with increased Lp(a) was also associated with increased risk of CAAD. At a more stringent P threshold of 0.01, 3 SNPs were significantly associated with CAAD (FDRϭ0.065). The most significant SNP, rs10455872, whose minor allele confers an OR of 2.1 per allele (95% CI, 1.3-3.2; Pϭ0.0013), was significant at a family-wise error rate of 0.05 (corresponding to Pϭ0.0024) estimated by permutation testing.
An additive genetic risk score in which alleles of each of the 9 SNPs associated with Lp(a) level were weighted according to their effect on Lp(a) level improved prediction of CAAD risk (OR, 1.5 per unit increase in risk score; Pϭ7.9ϫ10 Ϫ5 ). We also performed a comprehensive search of all 2-and 3-SNP haplotypes that could be formed from the 28 tagSNPs in the region. A 2-SNP haplotype formed by rs10455872 and rs6919346 was significantly associated with CAAD (nominal Pϭ5.2ϫ10 Ϫ5 ; Pϭ0.020 after Bonferroni correction for 378 2-SNP haplotypes tested). Among 3-SNP haplotypes, the rs10455872, rs6919346, and rs3123629 system was nearly significant (nominal Pϭ1.7ϫ10 Ϫ5 ; Bonferroni-corrected Pϭ0.054 for 3276 haplotypes tested).
Prediction of CAAD by SNPs Conditional on Lp(a)
After accounting for Lp(a) level, CAAD status was no longer associated with genetic variation in the 6q26-27 region. When Lp(a) level was included as a covariate in CAAD analyses, the minimum P value across the 28 tagSNPs analyzed was 0.088 (FDRϭ1). In a model including both Lp(a) level and the genetic risk score described, Lp(a) level (OR 1.40 per unit increase; Pϭ2.6ϫ10 Ϫ7 ), but not the risk score (OR 1.08; Pϭ0.52), was associated with CAAD. Neither the 2-SNP haplotype system formed by rs10455872 and rs6919346 (nominal Pϭ0.37) nor the 3-SNP haplotype system formed by the rs10455872, rs6919346, and rs3123629 (nominal Pϭ0.313) was a significant predictor of CAAD after accounting for Lp(a) level. Among all possible 2-and 3-SNP haplotypes, the minimum P values observed after conditioning on Lp(a) level (Pϭ0.044 and 0.0024, respectively) were well within the expectation for the null distribution.
Discussion
We identified 9 SNPs that are significantly associated with Lp(a) level when analyzed jointly and a partially overlapping set of 6 SNPs that were significantly associated with Lp(a) level when analyzed conditionally on KIV2 repeat length. Among the 9 SNPs predictive of Lp(a) independent of KIV2 length, 5 overlapped with the set of 7 SNPs described by Clarke et al. 22 Among the 6 SNPs predictive of Lp(a) conditional on KIV2 repeat, 4 overlapped with previous reports. 41, 42 In particular, rs10455872, which marks a haplotype carrying a low KIV2 copy number, and rs3798220, which is in LD with both the KIV2 copy number polymorphism and the SLC22A3-LPAL2-LPA haplotype associated with coronary artery disease, 43 are strongly associated with Lp(a) level. Interestingly, both of these SNPs continued to be associated with Lp(a) level after accounting for KIV2 repeat length, consistent with previous observations. 41, 42 It has been proposed that the nonsynonymous SNP rs3798220 may affect protein stability, 41 whereas rs10455872 may be in LD with regulatory variants. 44 Alternatively, their continued association with Lp(a) level after regressing on KIV2 effect may reflect inaccuracies in measurement of or statistical modeling of KIV2 repeat length. Although we identified multiple SNPs that jointly predict Lp(a) level, these SNPs accounted for just over than half of the variance in Lp(a) level explained by KIV2 alone. Our ability to only partially capture KIV2 copy number effects using SNP markers is consistent with the theoretical expectation of high expansion and contraction mutation rates for copy number variants and repeat polymorphisms, 45, 46 as well as previous empirical data suggesting weak LD between the KIV2 copy polymorphism and surrounding variation. 47 Moreover, a pentanucleotide repeat polymorphism upstream of LPA reportedly accounts for 10% to 14% of the variation in Lp(a) level. 48 In addition to the possibility that recurrent mutation has placed the same KIV2 and pentanucleotide repeat alleles on multiple haplotype backgrounds, another plausible explanation for the observation that multiple tagSNPs are jointly associated with Lp(a) level is the existence of numerous rare variants in the region, which can lead to high rates of synthetic association. 49 Our finding that tagSNPs improve prediction of Lp(a) level when combined with KIV2 genotype is consistent with a recent report by Lanktree et al. 42 However, in white individuals, Lanktree et al 42 report that only 36% of the variance in Lp(a) level can be explained by SNPs and KIV2 copy number. In contrast, in a large coronary artery disease cohort, Clarke et al 22 report that 36% of Lp(a) level can be explained by rs10455872 and rs3798220 alone. In our CAAD cohort, we found that these two SNPs explain only 22% (20% in controls) of Lp(a) variance, whereas SNPs and the KIV2 repeat explain 60% (57% in controls). One explanation for such heterogeneous estimates is that ascertainment on vascular disease and for KIV2 typing introduces an upward bias into estimates of percent variance explained in Lp(a); these limitations require that our estimates of the percent variation in Lp(a) should be interpreted with some caution. However, with regard to ascertainment on CAAD, the differences between the percent variations explained in our total sample compared to controls were only modest. In randomly ascertained families in which variance explained would be expected to be less, Boerwinkle et al 12 estimate that 69% of the variance in Lp(a) is attributable to KIV2 copy number and 90% of the variance in Lp(a) is attributable to variation at the LPA locus in general. These mutually inconsistent results highlight the difficulties in accurately assaying and modeling Lp(a) and KIV2 copy number, and underscore the importance of identifying alternative genetic markers in the region.
Our observation that LPA region SNPs and haplotypes predict CAAD extends that of Clarke et al, 22 who found that 6q26-27 SNPs are associated with coronary artery disease. In fact, rs10455872 confers a higher risk of carotid disease (OR 2.1) than any SNP among a panel of 34 markers associated with elevated low-density lipoprotein or decreased highdensity lipoprotein (highest OR 1.8). 21 In general, the genetic effects on CAAD that we observe are consistent with those reported by Clarke et al 22 and others for the LPAL2-LPA-PLG locus. Although because of its low minor allele frequency rs3798220 failed to achieve statistical significance in our study, the OR for the minor allele (1.8) is within the confidence interval for the effect of this variant on coronary artery disease risk reported in other studies. 22, 41, 50 We also found, in agreement with Clarke et al, 22 that conditioning on the Lp(a) level eliminated the association signal in the 6p26-27 region. This has several implications. First, because SNP genotypes undergo Mendelian randomization, their use as an instrumental variable 51 indicates that Lp(a) levels are causal for CAAD as well as for coronary artery disease, as previously suggested, 17 rather than the reverse. Second, because conditioning on Lp(a) level abolished any evidence of association between tagSNPs or haplotypes and CAAD, this argues against the presence of common structural variation, such as nonsynonymous changes, within LPA that effect protein function without affecting protein level. Third, despite a lack of standardization, 23 direct measurement of Lp(a) surpasses use of genetic polymorphisms as a surrogate marker.
Conclusion
In summary, we identified 9 SNPs that jointly accounted for 30% of the variation in Lp(a) levels. This was less explained variance than by use of KIV2 repeat number alone; however, by combining 6 SNPs with KIV2 repeat number, we accounted for 60% of the variance in Lp(a) levels. Five SNPs, all of which were strongly associated with Lp(a) levels, predicted CAAD risk, but these associations, as well as haplotype-based CAAD association signals within the LPAL2-LPA-PLG region, appeared to be driven exclusively by interindividual variation in Lp(a) levels.
Supplementary Table 1. Power to detect association between genetic variants and
CAAD.
Power estimates are based on 1000 simulations per parameter set for a sample size of 530 CAAD cases and 770 controls, assuming a population prevalence of 0.04. Association tests were performed using logistic regression as described in Methods. 
